Dr. Anderson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3555 Round Barn Cir
Ste 100
Santa Rosa, CA 95403Phone+1 707-528-1050
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1992 - 1995
Johns Hopkins UniversityResidency, Internal Medicine, 1988 - 1991
Duke University School of MedicineClass of 1988
Certifications & Licensure
CA State Medical License 2000 - 2025
MD State Medical License 1991 - 1992- American Board of Internal Medicine Medical Oncology
Clinical Trials
- PRO1184 for Advanced Solid Tumors Start of enrollment: 2022 Dec 07
Roles: Contact
- Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 Start of enrollment: 2023 Sep 22
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 7 citationsTrastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study.Bob T Li, Funda Meric-Bernstam, Aditya Bardia, Yoichi Naito, Salvatore Siena
The Lancet. Oncology. 2024-06-01 - 1 citationsOperational Metrics for the ELAINE 2 Study Combining a Traditional Approach With a Just-in-TIME Model.Sibel Blau, Julio Antonio Peguero, Halle C F Moore, Ian Churchill Anderson, Minal A Barve
JCO Clinical Cancer Informatics. 2023-06-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
